Elevation Oncology, which spent the spring fending off activist investor demands to wind down, has become the latest ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma ...

NewAmsterdam Pharma’s push to show a cholesterol drug can prevent Alzheimer’s disease has passed another test. | NewAmsterdam ...

Dietmar Berger, M.D., Ph.D., joined Gilead Sciences as chief medical of | Dietmar Berger became Gilead Sciences’ new chief ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

Global trade uncertainty and evolving tariff policies are shifting how bioscience companies view their supply chains.   | ...

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D for the British pharma. | After nearly 25 years with Sanofi, Sanjay ...

A new paper published in Nature on June 4 shines light on how an enigmatic part of male aging—the loss of Y chromosomes—is ...

Startup Clairity scored a green light from the FDA for the agency's first artificial intelligence tool designed to predict ...

TegMine has identified Taiwan’s OBI as a company that can help advance its ambitions. The new deal secures TegMine the right ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

In return for the ex-China rights to its new addition, called velinotamig, Cullinan has agreed to pay Genrix Bio the upfront ...